As of September 30, 2026, Passage Bio, Inc. carries a market capitalization of 14.48M, placing it among publicly traded companies globally. Its enterprise value stands at -5.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 14.48M |
| Enterprise Value | -5.68M |
Passage Bio, Inc.'s next confirmed earnings release is scheduled for March 8, 2027.
| Earnings Date | 3/8/2027 |
As of September 30, 2026, Passage Bio, Inc. has 3.22M shares outstanding.
| Shares Outstanding | 3.22M |
These figures are as of September 30, 2026.
| PB Ratio | 289.60 |
| P/TBV Ratio | 289.60 |
| P/FCF Ratio | -0.44 |
| P/OCF Ratio | -0.44 |
As of September 30, 2026, Passage Bio, Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.00 |
| Quick Ratio | 0.97 |
Over the twelve months ended September 30, 2026, Passage Bio, Inc. posted a negative return on equity (ROE) of -212.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -69.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 24.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -212.27 |
| Return on Assets (ROA) | -69.68 |
| Employee Count | 24.00 |
As of the close on November 16, 2026, Passage Bio, Inc.'s stock has declined approximately 53.33% over the past 52 weeks. The 50-day moving average sits at 4.10, while the 200-day moving average is 5.78.
| 52-Week Price Change | -53.33% |
| 50-Day Moving Average | 4.10 |
| 200-Day Moving Average | 5.78 |
Over the twelve months ended September 30, 2026, Passage Bio, Inc. generated - - in revenue and converted that into -33.08M in net income, yielding earnings per share of -10.33. EBITDA reached -34.98M, while operating income came in at -34.38M.
| Operating Income | -34.38M |
| Pretax Income | -33.08M |
| Net Income | -33.08M |
| EBITDA | -34.98M |
| EBIT | -35.31M |
| Earnings Per Share (EPS) | -10.33 |
As of September 30, 2026, Passage Bio, Inc. holds 20.16M in cash and equivalents against - - in total debt, resulting in a net debt position of -20.16M. Total book value stands at 50,000.00, with working capital of 50,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 20.16M |
| Net Debt | -20.16M |
| Equity (Book Value) | 50,000.00 |
| Book Value Per Share | 0.02 |
| Working Capital | 50,000.00 |
Passage Bio, Inc. produced -32.64M in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | -32.64M |
| Free Cash Flow | -32.64M |
| FCF Per Share | -10.19 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -226.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.06, meaning Passage Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.06 |
| FCF Yield | -226.43 |
Passage Bio, Inc.'s most recent stock split took place on July 14, 2025 with a 20:1 split ratio.
| Last Split Date | 7/14/2025 |
| Split Ratio | 20:1 |
As of September 30, 2026, Passage Bio, Inc. has an Altman Z-Score of -53.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -53.84 |